Blood Pressure and Statin Effects on Cognition: a Review
Purpose of Review
This is a review of available data on the effects of blood pressure and statins on cognition.
Recent randomized clinical trials have shown that intensive control of systolic blood pressure in older adults prevented the development of mild cognitive impairment (MCI) and the combined effects of MCI and probable dementia. Previous randomized clinical trials have suggested that statin use may prevent a decline in cognition; however, no randomized clinical trials have clearly shown evidence of statin’s either positive or negative effect on cognition.
Continued follow-up of SPRINT-MIND participants is crucial to evaluate the long-term effects of intensive systolic blood pressure control on the prevention of cognitive decline. A well-conducted and adequately powered randomized control trial is needed to evaluate the effect of statins on cognition, especially for primary prevention of the cognitive decline in aging.
KeywordsBlood pressure Statin Hypertension Cognition Cognitive impairment Dementia
Compliance with Ethical Standards
Conflict of Interest
Dr. Williamson reports grants from the National Institutes of Health, during the conduct of the study; Dr. Yang declares no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.2019 Alzheimer’s disease facts and figures includes a special report on Alzheimer’s detection in the primary care setting: connecting patients and physicians. https://alz.org/media/Documents/alzheimers-facts-and-figures-2019-r.pdf. Accessed April 2, 2019.
- 9.O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney cause and logic of therapy epidemiological studies and clinical trials. Hypertension. 2005;46:200–4. https://doi.org/10.1161/01.HYP.0000168052.00426.65.CrossRefPubMedGoogle Scholar
- 10.•• Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs standard blood pressure control on probable dementia. JAMA. 2019;321(6):553. https://doi.org/10.1001/jama.2018.21442 With a median of 5.5 years of follow-up, SPRINT-MIND demonstrated a positive effect of the mean 3.3 years of intensive blood pressure control for lowering rates of mild cognitive impairment (MCI). Results were not conclusive for probable dementia. The estimated reduction in risk for probable dementia was in the same direction and of the same magnitude as for MCI (19%, p = 0.008), but the hazard ratio estimate for probable dementia was not statistically significant (17%, p = 0.10). Consistent with this conclusion, the composite outcome of MCI or PD demonstrated a 15% reduction (HR of 0.85, p = 0.01). CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113–30. https://doi.org/10.1007/s40263-015-0230-6.CrossRefPubMedGoogle Scholar
- 13.• Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 2017;74(10):1246. https://doi.org/10.1001/JAMANEUROL.2017.1658 Midlife vascular risk factors are associated with increased risk of dementia in black and white ARIC Study participants. Vascular risk factors include the following: midlife smoking (HR, 1.41; 95% CI, 1.23–1.61), diabetes (HR, 1.77; 95% CI, 1.53–2.04), prehypertension (HR, 1.31; 95% CI, 1.14–1.51), and hypertension (HR, 1.39; 95% CI, 1.22–1.59). The HR for dementia for diabetes was almost as high as that for APOE ε4 genotype. CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174(3):324–33. https://doi.org/10.1001/jamainternmed.2013.13656.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Ambrosius WT, Sink KM, Foy C, et al. The design and rationale of a multi-center clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532–46. https://doi.org/10.1177/1740774514537404.CrossRefPubMedGoogle Scholar
- 20.Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 suppl 2):49–73. https://doi.org/10.1161/01.cir.0000437741.48606.98.CrossRefGoogle Scholar
- 22.Bonow RO. Primary prevention of cardiovascular disease: a call to action. Circulation. 2002;106(25):3140–1. https://doi.org/10.1161/01.CIR.0000048067.86569.E1.CrossRefPubMedGoogle Scholar
- 23.Johansen ME, Green LA. Statin use in very elderly individuals , 1999–2012 Rates of kidney transplantation from living and deceased donors for Blacks and Whites in the United States , 1998 to 2011. JAMA Intern Med. 2015;175(10):20–1. https://doi.org/10.1001/jamainternmed.2015.4302.Author.CrossRefGoogle Scholar
- 30.Kivipelto M, Helkala E-L, Laakso MP, et al. Apolipoprotein E ϵ4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149. https://doi.org/10.7326/0003-4819-137-3-200208060-00006.CrossRefPubMedGoogle Scholar
- 31.• Kuller LH, Lopez OL, Becker JT, et al. Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health STudy-Cognition Study. Alzheimer’s Dement. 2016;12(2):170–83. https://doi.org/10.1016/j.jalz.2015.08.165 More participants with normal cognition had coronary artery calcium scores < 10 compared to those with dementia or died. CrossRefGoogle Scholar
- 32.• Kuller LH, Lopez OL, Mackey RH, et al. Subclinical cardiovascular disease and death, dementia, and coronary heart disease in individuals age 80+. J Am Coll Cardiol. 2016;67(9):1013–22. https://doi.org/10.1016/j.jacc.2015.12.034 Subclinical measure of cardiovascular disease, CAC, or coronary artery calcium is associated with the incidence of dementia in individuals age 80+. White women with low CAC scores had significantly decreased incidence of dementia. CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Mainous A. G; Eschenbach, Stephanie L; Wells, Brian J; Everett, Charles J; Gill JM. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer’s disease: results from an 18-year population-based cohort. Fam Med. 2005;37(1):36–42 https://fammedarchives.blob.core.windows.net/imagesandpdfs/fmhub/fm2005/January/Arch36.pdf.PubMedGoogle Scholar
- 36.Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County Study. Alzheimer Dis Assoc Disord. 2006;20(2):93–100. https://doi.org/10.1097/01.wad.0000213814.43047.86.CrossRefPubMedGoogle Scholar
- 38.Solomon A, Kåreholt I, Ngandu T, et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 2009;30:1006–9. https://doi.org/10.1016/j.neurobiolaging.2007.09.012.CrossRefPubMedGoogle Scholar
- 41.Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64(10):1689–95. https://doi.org/10.1212/01.WNL.0000161870.78572.A5.CrossRefPubMedGoogle Scholar
- 44.Longstreth WT, Arnold AM, Beauchamp NJ, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the cardiovascular health study. Stroke. 2005;36(1):56–61. https://doi.org/10.1161/01.STR.0000149625.99732.69.CrossRefPubMedGoogle Scholar
- 47.Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: the Three-City Study. Atherosclerosis. 2010;210:243–8. https://doi.org/10.1016/j.atherosclerosis.2009.10.043.CrossRefPubMedGoogle Scholar
- 49.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7–22. https://doi.org/10.1016/S0140-6736(02)09327-3
- 50.LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Vol 352.; 2005. www.nejm. Accessed May 14, 2019.
- 52.Cholesterol Treatment Trialists’ Collaboration CTT. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet (London, England). 2019;393(10170):407–15. https://doi.org/10.1016/S0140-6736(18)31942-1.CrossRefGoogle Scholar
- 53.Gorelick P, Black E, DeCarli C, et al. Vascular contributions to cognitive impairment and dementia: Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia. Stroke. 2011;42(9):2672–713. https://doi.org/10.1161/STR.0b013e3182299496.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Ten Dam VH, Van Den Heuvel DMJ, Van Buchem MA, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology. 2005;64(10):1807–9. https://doi.org/10.1212/01.WNL.0000161844.00797.73.CrossRefPubMedGoogle Scholar
- 57.• Bath PM, Scutt P, Blackburn DJ, et al. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot “Prevention of Decline in Cognition after Stroke Trial” (PODCAST) randomised controlled trial. PLoS One. 2017. https://doi.org/10.1371/journal.pone.0164608 In patients with recent stroke and normal cognition, intensive blood pressure and lipid lowering were feasible and safe but did not alter cognition as measured by Addenbrooke’s Cognitive Examination-Revised (ACE-R) over two years. Intensive lipid lowering therapy was associated with some secondary outcomes such as trail making A, modified Rankin Scale, and Euro-Qol Visual Analogue Scale, suggesting a need for further clinical trial. CrossRefGoogle Scholar
- 58.Lütjohann D, Papassotiropoulos A, Björkhem I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. Supplementary key words brain cholesterol • Apolipoprotein E • Cell Membrane • Isotope Dilution-Mass Spectrometry • Hippocampus • Senile Plaques • Depression • Blood-Brain Barrier. Vol 41.; 2000. www.jlr.org. Accessed May 23, 2019.
- 60.Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein e to synthetic amyloid ,B peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Vol 90.; 1993. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC47295/pdf/pnas01474-0198.pdf. Accessed May 23, 2019.
- 62.Thal Rudolf D, Capetillo-Zarate E, Shultz C, et al. Apolipoprotein E co-localizes with newly formed amyloid b-protein (Ab) deposits lacking immunoreactivity against N-terminal epitopes of Ab in a genotype-dependent manner. Acta Neuropathol. 2005;110:459–71. https://doi.org/10.1007/s00401-005-1053-1.CrossRefGoogle Scholar
- 66.Yang D, Knight RA, Han Y, et al. Statins protect the blood brain barrier acutely after experimental intracerebral hemorrhage. J Behav Brain Sci. 2013;3(1):100–6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583226/pdf/nihms434278.pdf. Accessed May 23, 2019.CrossRefGoogle Scholar
- 69.Reiss AB, Siller KA, Rahman MM, Chan ESL, Ghiso J, De Leon MJ. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease. Neurobiol Aging. 2004;25:977–89. https://doi.org/10.1016/j.neurobiolaging.2003.11.009.CrossRefPubMedGoogle Scholar
- 70.• Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. 2Circulation. 2018;137(12):1260–9. https://doi.org/10.1161/CIRCULATIONAHA.117.029785 PCSK9 loss-of-function (LOF) variants result in lifelong low LDL-C. The REGARDS investigators investigated the association between PCSK9 LOF variants and neurocognitive impairment among African-American participants with the variants compared with those without the variants. Low PCSK9 levels and low LDL-C were not associated with neurocognitive effects in African Americans. CrossRefGoogle Scholar
- 71.• Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633–43. https://doi.org/10.1056/NEJMoa1701131 Evolocumab is a PCSK9 inhibitor that has shown to reduce rate of cardiovascular events among patients with established cardiovascular disease. In a subgroup of patients from randomized, placebo-controlled trial of evolocumab added to statin therapy, cognitive function was prospectively assessed in 1204 patients followed for a median of 19 months. There were no significant between-group differences in evolocumab and placebo groups. CrossRefPubMedGoogle Scholar
- 72.FDA. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs. Published 2016.
- 73.Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory Study. J Stroke Cerebrovasc Dis. 2012;21(6):436–44. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002.CrossRefPubMedGoogle Scholar